INVESTOR INFORMATION.

Cannabis Science alleviates suffering and promotes health through cannabinoid science. A pioneering biotech company, Cannabis Science creates cannabinoid-based extract formulations for various medical conditions, including more than 8 different types of Cancer.

Each individual one of these formulations has revenue and earnings potential in the hundreds of millions of dollars based on the current global pharmaceutical industry. The potential revenue and earnings are combined with additional profit centers including an educational model, nutraceutical products, and a strategic partnership with MedBox® Solutions. These additional profit centers bring a higher level of confidence to realizing our overall financial strategy and plan to bring Cannabis Science into positive earnings per share by 2015.

The cannabinoid market and industry is best explained using the alcohol prohibition black market model in the 1920’s, and then as a pharmaceutical retail market in the 1930’s.

The cannabinoid market is estimated at $30-$50 billion. Internal estimates raise that number to $74 billion upon speculation of the Federal Medical Cannabis Program in 2017.

Cannabis Science's President Emeritus, Dr. Robert Melamede, Ph.D., is focused on the quantum physics relationship with biology, and the role the cannabinoid strain plays in the string of life. His research and science of the cannabinoid system along with the relationship between the endocannabinoid system and phytocannabinoids is pioneering. The Cannabis Science Scientific Advisory Board is comprised of several doctors who embrace and support Dr. Melamede’s vision. Board members are all considered global leaders.

Cannabis Science's executive management team is built through a partnership of independent consultants whose interests are aligned with the success of shareholders and Cannabis Science. This model and their executive management plan have allowed Cannabis Science to attract strategic partnerships that generate revenues, as with Vincent Mehdizadeh, from MedBox. It also has allowed Cannabis Science to strengthen the services of the company both with investors through Robert Kane, Investor Relations Manager, and with patients.

Cannabis Science is the first publicly traded cannabinoid company on the market, whose symbol is CBIS, and is the only publicly traded company in existence that is involved in cannabinoid-extract based formulations. This model and leadership position is of great value as the company matures over the next twenty years and expands globally into a potential billion dollar biotech global leader.

In conclusion, Cannabis Science is a company doing the right things, for the right reasons, with the right people, a company started by someone who was ill and found a way to heal themselves. That person shared their solution with others and they have shared with hundreds of millions of patients who are suffering; chronic pain patients, cancer patients, MS patients, soldiers and veterans with PTSD, those who are terminally ill, and patients with dozens of other conditions are now all aware of the medicinal value of cannabinoid. Now is simply the best opportunity for Cannabis Science to help and heal those who are suffering through their formulations and services.

ORDER ONLINE.

Cannabis Science’ proprietary, short-time vacuum distillation process determined the ideal pressure, temperature, and time to avoid the loss of CBDA and all of the important acids of cannabinoids. As part of its testing process, the Company utilized CBD extract with 7.3% CBD and less than 0.2% THC levels. Through the first step of CBIS’ purification process, the Company produced a purified CBD extract with 26% CBD and over 0.6% THC levels. Based on this cleaned extract Cannabis Science EU GmbH produced a purified water-soluble CBD powder with 3.5% CBDA, 3.5% CBD, and less than 0.02% THC levels. Generally, cannabinoids become unstable when mixed with water due to the oxidation process. Through the Company’s vacuum distillation process and emulsification solution, CBIS can provide its customers with the highest CBDA extracts in powder form, thereby bypassing this oxidation and providing a potent product that maintains full nutritional CBDA and CBD levels with a much longer consumption expiry date than in water-diluted common CBD products, commonly poor in CBDA.

PERSONAL LOYALTY GIFT.

Welcome to your “Personal Loyalty Gift” from Mr. Raymond. C. Dabney This is a very special time and I want to extend my personal “Thanks” to everyone who has supported me throughout the years. I have been blessed with “Very Loyal People” who have supported me for years on end. I will recognize your names, and I look forward to reconnecting with many of you via phone. I have lost contact with some of you and you know who you are, I will be reaching out to you as well. Each of you are included in this “Personal Thank You Gift”, whether you own CBIS Shares or not. Again Thank YOU All, for your confidence, your support, and your Loyalty throughout the years. For this Loyalty I will be “Giving you some of my personal shares” of Cannabis Science Inc. This is my personal confirmation of my Appreciation of you and your Loyalty. To the CBIS shareholders that I will “Gift some of my Shares”, I want and expect nothing in return, as a matter of fact, in the future everyone can look forward to “more Loyalty Gifts” as we progress forward with our High-Growth Business Models in our group of Companies.

Loyalty is a SPECIAL word, and I value it as such. Finding Loyal people for “your/any team” is a very difficult task and I value Greatly the ones I have. Unfortunately, sometimes people are not loyal and have their own deceitful strategies to unhinge you from your path of success. It is ironic how things do work out, when faced with such adversaries. Our Loyal people in our lives seem to rise up and shine in these moments “to fight the deceptions” they seem to fight with the Wrath of God to protect our Companies and all the Loyal individuals in our lives.

So with this in mind, I definitely want to be able to reward the “Loyal people in our Lives” the ones who stand beside you, who support you, protect you, and lift you up by any means they can, in anyway they can. As I am sure you can imagine, I am just as excited as you are to process these “Gifts” and give them to you as quickly as possible. We appreciate your patience as we process your “Loyalty Gift” and my legal team assesses the simplest mechanism we can use to accomplish our goal.

To initiate your “Loyalty Gift” please fill out the required (*) fields below:

Thanks Again for your Loyalty,
Talk soon.

Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder
Cannabis Science, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel:1-888-263-0832

CORPORATE OVERVIEW

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide innovative treatment options for unmet medical needs.

Cannabis use has an extensive history dating back thousands of years, and currently there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.

We are dedicated to working closely with local, national and international regulatory agencies to provide access to high quality, first class cannabinoid pharmaceuticals to those critically in need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the cultivation and production facilities that are cGMP compliant, surpassing high quality standard industrial and food processing requirements.

The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses and neurobehavioral disorders.

Our products, broadly described, are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant. Our immediate focus is to treat one of the most important diseases in the world, cancer.

In 2013, Cannabis Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders" (CS-NEURO-1). The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders.

BASIS & PHILOSOPHY

Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.

To date hundreds of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

SOME KEY PHYTOCANNABINOIDS ARE:

• tetrahydrocannabinol (THC)

• cannabidiol (CBD)

• cannabigerol (CBG)

• cannabichromene (CBC)

• cannabinol (CBN)

These cannabinoids belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC. Some applications of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.

Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.

The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

The endocannabinoid system possessed by all vertebrates regulates all body systems and maintains homeostasis. As such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

While concentrating on our core activities of discovering and developing treatments that will make a meaningful difference in patients’ lives, we remain mindful that we have other responsibilities to the clinicians who utilize our drugs, health authorities around the world, our shareholders, our employees, and the communities in which we live and work. We continually strive to improve our corporate responsibility standards and activities, implementing comprehensive ethical standards and undertaking patient and community progressive initiatives.

These principles reflect the mission of Cannabis Science to provide innovative therapeutics for unmet medical needs.

As the industry leader, Cannabis Science consults and leads other emerging businesses that Cannabis Science believes has a preferred business model, one which will mature into a key business model in the future. Our consulting is on the entire "seed to sale" process with a focus on bio-pharmaceutical development.

Cannabis Science is one of the longest standing companies in the cannabis business.

We feel that the correct way is to look at the industry from a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions. Scientifically, we know this is the beginning of one of the greatest expansions of medicine and industry we will ever experience in our lifetime.